EUCTR2014-004483-38-DE进行中（未招募）1 期
TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trial
Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)0 个研究点目标入组 55 人开始时间: 2015年4月28日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age 18 to 55 years
- •Definite diagnosis of RRMS (according to revised McDonald criteria, Polman et al. 2011, Ann Neurol 69:292-302)
- •At least 1 documented relapse during the previous year OR at least 2 documented relapses during the previous 2 years
- •At least one contrast-enhancing lesion (CEL) on the screening MRI scan at week -4
- •EDSS of 0 – 5 (inclusive) at screeing (week -4)
- •Women of childbearing potential (WOCBP) must use 2 adequate forms of contraception to avoid pregnancy throughout the trial (such as a double barrier method) and for up to 8 weeks after the last dose of TMP001 in such a manner that the risk of pregnancy is minimized
- •Written informed consent obtained prior to the initiation of any protocol-required procedures
- •Compliance to study procedure and study protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 55
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •History of chronic disease of the immune system other than MS or a known immunodeficiency syndrome
- •Clinically severe active infection (e.g., pneumonia, septicaemia) within the 1 month prior to Screening.
- •Diagnosis of neuromyelitis optica, clinically isolated syndrome, secondary progressive multiple sclerosis, or primary progressive multiple sclerosis
- •History of drug or alcohol abuse within 2 years of inclusion to the study
- •Relapse or corticosteroid treatment within 30 days before screening (week -4)
- •Interferon-beta, glatiramer acetate, teriflunomide, dimethyl fumarate or fingolimod therapy had to have been stopped 3 or more months before enrolment
- •Immunosuppressive medication such as azathioprine or methotrexate, Ciclosporin, cyclophosphamide, mycophenolate mofetil, mitoxantrone or cladribine at any time
- •Any previous therapy with alemtuzumab, ocrelizumab, ofatumumab, rituximab, belimumab, natalizumab, total body irradiation, or bone marrow transplantation
- •Any investigational drug or placebo within 12 weeks prior to enrolment OR > 5 half-lives prior to screening (week -4), whichever is longer
- •Women that are pregnant or currently breast feeding
- •Concurrent participation in other clinical trials
- •History of, or current diagnosis of, malignancy (including previously treated skin cancer other than successfully treated basal and squamous skin cancer with no evidence of recurrence within 5 years)
- •Inability to complete an MRI or contraindications for MRI, including but not limited to claustrophobia, presence of a pacemaker, cochlear implants, ferromagnetic devices or clips, intracranial vascular clips, insulin pumps, or nerve stimulators
- •Hypersensitivity to contrast agent (Gadolinium, resp. Gadopentetat-Dimeglumin)
- •Any reason in the discretion of the investigator regarding the safe participation of the patient in the study or for any other reason, the investigator considers the patient inappropriate for participation in the study.
- •White blood count (WBC) <3000 mm3 at screening (week -4)
- •Lymphocytes < 800 mm3 at screening (week -4)
- •Known renal insufficiency stage III or higher (eGFR = 59ml/min/1.73 m2; according to the Kidney Disease Outcomes Quality Initiative (KDOQI))
- •Exclusion criteria regarding the study medication:
- •Patients with known hypersensitivity to study medication
- •Patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs)
- •Patients with a history of peptic ulcer disease and/or gastrointestinal bleeding
- •Chronic or acute renal, hepatic or metabolic disorder
- •Patients with a history of myocardial infarction, ischemic stroke or known heart failure
- •Patients with known thrombophilia or abnormal clinically significant coagulation parameter at screening (week -4)
研究者
相似试验
已完成
2 期
TMP001 in Relapsing-remitting Multiple SclerosisRemitting-Relapsing Multiple SclerosisNCT02686788Dr. Frank Behrens9
Unknown
4 期
Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to GilenyaRelapsing Remitting Multiple SclerosisNCT02325440University Hospital Muenster15
已完成
不适用
Repetitive Deep Transcranial Magnetic Stimulation in Multiple SclerosisMultiple SclerosisNCT01106365Charite University, Berlin, Germany36
进行中（未招募）
1 期
Multiple sclerosis therapy with transdermal myelin peptide stimulation.relapsing-remitting multiple sclerosisEUCTR2016-002180-33-PLCentrum Neurologii Krzysztof Selmaj220
招募中
1 期
Imatinib treatment for Multiple Sclerosis (MS) RelapsesPatients with clinically definite Multiple Sclerosis (MS) according to the McDonald Criteria, or possible MS (also named clinically isolated syndrome-CIS, as a first manifestation of MS, where there are radiological and/or cerebrospinal fluid signs consistent with MS), which display an acute relapseMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: LLTClassification code 10028247Term: Multiple sclerosis like syndromeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-000620-34-NODepartment of Clinical Neuroscience, Karolinska Institutet